Podcasts about behavioral pharmacology

Psychedelic researcher Dr. Matthew Johnson from Johns Hopkins University joins Dr. Mike Hart to delve deep into the world of psychedelics. Their discussion extends from the therapeutic potential of psychedelic substances in treating mental health disorders such as depression, PTSD, and addiction, to the controversy surrounding their use. Dr. Johnson shares his experiences in pioneering psychedelic research, the therapeutic model he's developing, and insights into the microdosing and macrodosing of substances. They touch upon the societal impact of alcohol and drug misuse, the power of the placebo effect, and how psychedelics interact with traditional treatments like SSRIs. The episode concludes with a nuanced look at the challenges and future direction of the psychedelic space. Time-codes:[00:00:00] Dr. Mike Hart introduces Dr. Matthew Johnson. Johnson's work in the psychedelic field is presented, setting the stage for the conversation. [00:02:10] Dr. Hart highlights the growing interest in using psychedelics as treatments for mental health conditions, opening the floor for a deep discussion on the potential of these substances. [00:07:57] Dr. Johnson delves into historical LSD research related to alcoholism, sparking interest in the anti-addiction potential of psychedelics. [00:15:42] Discussion around the potential therapeutic effects of microdosing psychedelics, including its potential role in treating depression and the possible influence of the placebo effect. [00:24:02] Johnson elucidates on the process of "integration" in psychedelic therapy, which involves understanding the implications of psychedelic experiences for one's psychiatric issues. [00:30:30] Dr. Johnson introduces the concept of a generalized psychedelic therapy model, suggesting its applicability across various mental disorders. [00:32:30] An insight into Dr. Johnson's survey work on the therapeutic use of psychedelics, where people have quit or reduced their consumption of harmful substances. [00:36:59] Dr. Johnson underscores that different psychedelics have similar efficacy rates regardless of the treated condition, leading to a deeper understanding of their impact. [00:42:30] Discussion on how the synchronization of different brain areas could enhance creativity, touching upon a less-explored benefit of psychedelic use. [00:49:28] Dr. Johnson discusses the overuse of certain medications like SSRIs and ADHD drugs, while stressing that he does not advocate for their complete removal from the treatment toolbox. [00:53:31] Dr. Johnson addresses the problem of puritanism in the psychedelic space and its impact on recognizing other effective treatments. [01:03:00] Dr. Johnson talks about the effect of antidepressants on the psychedelic experience, providing critical information for those on such treatments considering psychedelic therapy. [01:05:30] They discuss the challenges of withdrawing from prescribed medications for alternative treatments like Ayahuasca, acknowledging the complexities faced by patients. [01:10:37] Matthew Johnson shares his experience at a psychedelic conference, introducing the audience to a broader context of the psychedelic space. [01:13:15] Johnson expresses concerns about future developments in the psychedelic field, alluding to accusations against MAPS, making for an intriguing and thought-provoking ending.

In this podcast, we're talking with Azizi Ray, who was a student of Mercer University College of Pharmacy in Atlanta, Georgia at the time of the interview.Listen and learn as she shares her experience in preparing for a thesis defense as a dual Pharm.D./Ph.D. Behavioral Pharmacology candidate.She will answer questions about the opportunities and challenges of pursuing a dual degree program, offer insight for successfully identifying allies to lend support, and provide practical advice for students or those interested in pursuing the same path in the future!Guest Speaker BioDr. Azizi Ray found a welcoming environment at Mercer University's College of Pharmacy, where in 2021 she earned a Pharm.D./Ph.D. degree. She plans to continue her studies at the University of Arkansas, researching how computational models of neural activity can inform treatments for drug abuse, specifically stimulant abuse in communities of color.Mercer University College of Pharmacy (video)Azizi Ray Outstanding Graduate 2021Connect with Dr. Ray on LinkedInAbout Innovation CompoundingInnovation Compounding is licensed as a 503A, compounding pharmacy, accredited by The Pharmacy Compounding Accreditation Board (PCAB®).Today, we support over 7,000 prescribers, 80,000+ patients, and annually provide 100,000+ prescriptions to 46 states across the U.S. We commit to individualized pharmaceutical care by being relentless in our drive for personalized medicine, compassionate toward our patients and doctors, and being a #WellnessAdvocate for our patients' lives and state of well being.Learn more about the work we do and how we can help to build your practice by visiting us online:Innovation Compounding Website Support the show

Dr. Albert Garcia-Romeu obtained his Ph.D. in Psychology from the Institute of Transpersonal Psychology in 2012 for his research on self-transcendence and meditation. He completed his post-doc in Behavioral Pharmacology. He currently is an Assistant Professor of Psychiatry and Behavioral Sciences at Johns Hopkins University School of Medicine and is a guest researcher at the National Institute for Drug Abuse Intramural Neuroimaging Research Branch. Dr. Garcia-Romeu's Publications Online Study of Naturalisti Psilocybin Use Referenced Articles: Psychiatry & the psychedelic drugs. Past, present & future -Dr. James Rucker Human hallucinogen research: guidelines for safety -Dr. Matt Johnson Follow us: Website: https://www.journalofpsychedelicpsychiatry.org/ Twitter: https://twitter.com/psychedelic_org Facebook: https://www.facebook.com/JournalofPsychedelicPsychiatry/ Instagram: https://www.instagram.com/journalpsychedelicpsychiatry/ If you like what you heard in this episode please consider supporting us: https://anchor.fm/journalofpsychedelic/support --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app Support this podcast: https://anchor.fm/journalofpsychedelic/support

Dr. David Cox joins me in Session 99 to discuss the Experimental Analysis of Behavior, Behavioral Pharmacology, the use of Psilocybin Mushrooms for the treatment of various behavioral health challenges, and much, much more! David does a fine job describing his backstory, but if you're impatient like me, here is his bio from Research Gate: David has been working clinically in Applied Behavior Analysis (ABA) since 2006. He has worked with children, adolescents, and adults with diagnoses ranging from autism spectrum disorders and developmental disabilities​​ to substance use disorders and obesity. David is currently a research fellow in the Behavioral Pharmacology Research Unit in the Department of Psychiatry and Behavioral Sciences at the Johns Hopkins University School of Medicine. His current areas of focus are choice behavior, preference, behavioral economics, and the application of these areas to clinical intervention, clinical decision making, and ethical behavior. We cover a wide range of topics, and David cites a ton of research and resources, so I'm going to get right to the links: Say hello to David on Twitter. He's the co-author of this nifty book. The University of Florida's Behavioral Health and Technology Research Clinic. Previous podcasts on Behavioral Economics/Stuff from my friends: Session 11, Erin Rasmussen. Session 17: Derek Reed. Session 2: Steve Lawyer. Dews, 1955 (note, the figure below is the one David describes during the show). FIGURE 4 (DEWS, 1955) Baum, 1974. Nevin, Mandell, and Atak, 1983. McDowell 2005. Rasmussen and Newland 2009 (the Anti-Punishment effect). Odum 2011 (I'm a k, you're a k). Branch 2006, (How Research in Behavioral Pharmacology Informs Behavioral Science). Heyman 2013 (Addiction and Choice, Theory and New Data). Critchfield 2011 (Translational Contributions of EAB). NPR story on Dr. Matthew Johnson's psilocybin research. Johns Hopkins Center for Psychedelic and Consciousness Research. Multidisciplinary Association for Psychedelic Studies. Tim Ferriss podcast episode (panel with researchers at Johns Hopkins). This podcast is brought to you with support from the following: The University of Cincinnati Online. The UC Online program can be a rewarding way to advance in your career. Gain the cutting-edge knowledge and skills so you can help others while increasing your career options and earning potential. For more information, please visit behavioranalysisuc.online for more information. Go Lotus is an intuitive, easy to use, and dare I say beautiful system. It handles every aspect of practice management from data tracking and automatic SOAP notes, to scheduling and billing. They even offer a white-glove in-house billing service if you want billing fully managed outside your clinic. It is so simple your entire team can be up and running in less than an hour. For more information, go to golotus.com/register for a free demo. If you do sign up, tell them I sent you or use the coupon code Matt2019 and you will get 25% off for the first 3 months. They are so confident that you will love the system they allow you to cancel at any time. There is no risk and no commitment required. If you want more info, head over to golotus.com/register. I'm also excited to promote this upcoming workshop: Have you ever been part of a team composed of capable, accomplished members that underachieved or failed to launch an initiative successfully? Do you work with teams where members burn out, conflict, misbehave, or act in ways that contradict the purpose of the group? Are you currently working with other people toward a common goal and aiming to ensure that every member is empowered for maximum contribution and long-term sustainable engagement? Then consider attending the OBM 2.0 – The PROSOCIAL Teaming Model which will be taught by Drs. Darnell Lattal and Thomas Szabo. This workshop is being put on by my friends at Connections Behavior Planning and Intervention. It’s being held at Green River Community College, Auburn, Washington on January 18th and 19th. Attendees will learn the ProSocial model: evidence-based practices to promote employee engagement, cooperation, high-level performance, and complex organizational problem-solving. The ProSocial approach incorporates findings from Nobel Prize winning research conducted by Elinor Ostrom, with corresponding findings from research in evolutionary science, behavior analysis, ACT, and Organizational Behavior Management. Participants will practice core skills and then implement them in a series of challenging role-plays that simulate real-life organizational behavior crises. This workshop will walk attendees through the entire process of creating sustainable team-based outcomes through expert instruction and experiential learning. The workshop itself will provide 16 CEU’s, and there’s a remote follow-up option that can extend this to 22 CEU’s. Space is limited for this event, and the prices go up as we get closer to the dates, so you’re going to want to register for OBM 2.0 straight away. And to help defray costs, the folks at Connections have offered listeners a discount. So for more information, click here, and be sure to use the code podcast25! Lastly, I’d like to mention something I don’t bring up all that frequently. I have a membership program for the podcast; think of it as a DIY Patreon… It’s been running for a few years now, and it costs the princely sum of $9/month. Members get access to a private FB group in which they are able to get nearly instantaneous access to the videos of these podcast interviews. This interview, for instance, has been available since October 22nd. The best part is that members get the raw feed. That means no ads, and none of the introductory comments. You just get right to the interview. Another cool thing we do is hold Zoom Hangouts with former guests. We do this about 6 times a year, and it works like this: we schedule a Zoom call, a former guest comes on and joins us, and the members have the opportunity to ask them questions directly. The last episode with Pat Friman is a good example of this. And coming up on November 13th, I’ll be hosting Dr. Luis Morales Knight, who joined us a few months ago to talk about parenting, working with adolescents in a mental health setting, and so forth. I hope you’re able to join us!

Why would us girls crave a drink more at “that time of the month” than at other times? Is there any kind of link or is it all in our heads? Annie Grace tells us what she’s learned in her research about this topic. Find out what studies done by the Journal of Drug and Alcohol Dependence, as well as Behavioral Pharmacology, have to say about this theory. Did you miss This Naked Mind Live 2018? Do you maybe have a little bit of FOMO? Don't worry. I've got you covered. In fact, I had the entire event professionally recorded and it's available digitally. Transformation in your living room, yup, that is what it's all about. You can grab your digital ticket at thisnakedmind.com/digitalticket. As always, rate, review, and subscribe to this podcast as it truly helps the message reach somebody who might need to hear it today.

Episode 13: Entering the Job Market Chun Tao met with Drs. Martin and Ragin to discuss transitioning to the job market and things to consider when you are applying for jobs. Dr. Deborah Fish Ragin is a Professor of Psychology at Montclair State University. Her professional service includes a five-year appointment as an American Psychological Association (APA) Representative to the United Nations where she focused on global efforts to address the psychosocial impact of HIV/AIDS. She currently serves as a member of the Health Research Council of the Health Psychology Division (Division 38) of the American Psychological Association and as a member of the Committee on Associate and Baccalaureate Education (CABE) also for the American Psychological Association. Dr. Ragin’s research focuses on health systems and health policy, examining disparities in health care. She is the author of numerous articles on HIV/AIDS, domestic violence, health care disparities, healthy communities, and research ethics, and of a leading textbook entitled Health Psychology: An Interdisciplinary Approach to health, now in its third edition, published by Routledge/Taylor and Francis. She also serves as a reviewer on several international and national journals, including Social Science and Medicine, American Journal of Nursing, Health Psychology Open, Journal of Interpersonal Violence, and others. Dr. Martin Igunchi is a Professor and Chair, Department of Community Health Sciences, University of California, Los Angeles, School of Public Health. Dr. Iguchi received his AB in liberal arts from Vassar College, his MA, and Ph.D. in experimental psychology from Boston University, and postdoctoral training in Behavioral Pharmacology and Drug Abuse from Johns Hopkins. He is also a former Director of the RAND Corporation's Drug Policy Research Center. Dr. Iguchi's more recent research has examined the sexual transmission of HIV, development of brief motivational and contingency management approaches for the treatment of substance abuse, barriers to treatment entry, and drug policies. Dr. Iguchi is also studying aging performing artists, examining the quality of life, life transitions, retirement planning, legacy planning, and roles in the community.

Host: Paul Rokuskie Host Paul Rokuskie is joined by Drs. Declan Murphy and Will Spooren. Dr. Murphy is Professor of Psychiatry and Brain Maturation at Kings College, London, and Dr. Spooren is Group Leader of Behavioral Pharmacology at Roche Pharmaceuticals. Their topic for discussion is the large academic and industrial consortium known as European Autism Interventions, or EU-AIMS, which serves as a collaborative network bridging experts in autism across the spectrum of pharmacologic research and development.

Pitts, Raymond – Behavioral Mechanisms of Drug Action: What Are They, How Will We Know One When We See It, and How Might Quantitative Models Help? - Over 45 years of research in Behavioral Pharmacology has shown quite clearly that environmental variables are powerful determinants of the behavioral effects of drugs. Unfortunetly, providing a coherent, behavior-analytic framework within which to characterize the roles of environmental context, behavioral history, schedule of reinforcement, type of reinforcer, and deprivation level (to name a few) has proven to be quite a challenge. It has been suggested that effects of these and the myriad other environmental determinants might be viewed within a conceptual framework referred to as “behavioral mechanisms” of drug action. In this tutorial, I describe the notion of behavioral mechanisms of drug action and review some of the sorts of data that have been said to illustrate them. I focus on the potential for quantitative models as a set of tools for elucidating behavioral mechanisms. I conclued by exploring the applied/translational implications of the concept.

This podcast is relevant to professionals. In this episode R. Trent Codd, III, Ed.S. interviews Dr. Marc Branch about Behavioral Pharmacology. Some of the topics discussed in this episode include: Behavioral Pharmacology’s views on addiction  Discussion of Peter Dews and his research program Behavioral factors related to tolerance  Exposure and anti-anxiety agents  MARC BRANCH, PhD BIOGRAPHY Dr. Branch is best known for directing one of the country’s active programs in behavioral pharmacology. He has conducted a long line of research on agents such as pentobarbital, d-amphetamine, and cocaine. His research has primarily been concerned with behavioral factors that influence whether and the degree to which tolerance develops in the face of repeated exposure. His work has been supported continuously for 30 years by the National Institute of Mental Health (NIMH) and National Institute on Drug Abuse (NIDA) and has been published in flagship journals in both behavior analysis and pharmacology. In recognition of this consistent track record of excellence, he has been the recipient of a coveted research career award from NIMH. He is a fellow of both the American Psychological Association and the American Psychological Society.

Branch, Marc - Behavioral Pharmacology - Behavioral pharmacology is a discipline that emphasizes the interrelationships and interactions between behavioral variables and the actions of drugs. The tutorial will first outline the history and origins of behavioral pharmacology, and also the logic behind the field. Examples of how behavioral variables can modify drug effects, and how such phenomena can be studied systematically, will be presented. Finally, illustrations of how examination of drug effects can illuminate behavioral processes will be provided.